EATONTOWN, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Osteotech, Inc.
(Nasdaq: OSTE) announced today that Sam Owusu-Akyaw, Osteotech's President
and Chief Executive Officer, will deliver a presentation at First Albany
Capital's 2nd Annual Orthopedic Conference. Mr. Owusu-Akyaw will be
discussing Osteotech's productivity and profitability activities, new
products and technologies and distribution effectiveness initiatives. A
copy of the presentation is available on Osteotech's website at
http://www.osteotech.com until February 21, 2007.
Mr. Owusu-Akyaw will deliver a similar presentation at Roth Capital
Partners 19th Annual OC Conference on February 21, 2007 at 3:30 PM PST. A
live webcast of that presentation will be available the day of the
presentation through Osteotech's website at http://www.osteotech.com. A
replay of the presentation will be available for approximately two weeks
thereafter through Osteotech's website.
During the presentation, Mr. Owusu-Akyaw will describe:
* Osteotech's New Products and Technology Model - This model
identifies Osteotech's mission for the development of Osteo-Biologic
solutions. New products and technologies will be created with input
from surgeons. New technologies will focus on specific therapies
within certain market segments to develop new procedure specific
products.
* Market Positioning of the Plexur(TM) P Biocomposite - The Plexur(TM)
P Biocomposite will be positioned in the synthetic portion of the
bone graft substitute market against solid calcium sulfate, tri-
calcium phosphate and hydroxyapatite bone graft substitute forms.
Plexur(TM) P is a bone void filler and osteogenic carrier that can
be utilized as a bone graft extender or allograft substitute.
Osteotech previously announced on February 8, 2007 that the Food and
Drug Administration had cleared the Plexur(TM) P Biocomposite.
* Market Positioning of the Plexur(TM) M Biocomposite - The Plexur(TM)
M Biocomposite, which is still under development, will be positioned
in the synthetic portion of the bone graft substitute market with a
secondary focus on the orthopedic reconstructive bone cement and
orthopedic fixation and settable materials sub-markets. Plexur(TM)
M will compete against settable calcium sulfate and tri-calcium
phosphate forms and PMMA (bone cement) for certain procedural
applications. Plexur(TM) M will be a moldable bone void filler,
which can be utilized in the fixation of bone fragments and grout as
a secondary stabilizer.
* Enhanced DBM Platform - Osteotech's Enhanced DBM platform will be
utilized to develop procedural specific products with targeted
osteoinductive activity levels. Products will be optimized with a
procedure specific carrier with increasing activity levels depending
on surgical challenge. Osteotech's Enhanced DBM technology is still
under development.
* Introduction and Market Positioning of the Osteotech Tension Band -
Osteotech will introduce a new collagen based product for spinal
stabilization and fusion, which is currently under development. The
Tension Band will compete with polymeric and wire cable tension
bands and will be utilized for dynamic stabilization in the spine.
Unlike other competitive products, Osteotech's Tension Band is
capable of remodeling into bone.
* Distribution-Product Continuum - Osteotech's Distribution-Product
Continuum focuses on a transition from an agent/distributor
distribution model representing the full line of Osteotech products
to a hybrid Osteo-Biologic specialist and agent/distributor model in
2007. The continuum details a continued transition to an advanced
hybrid distribution model of Osteo-Biologic specialists and
agents/distributors providing a full Osteo-Biologic product
portfolio focus.
All information in this press release and in the Company's First Albany
Capital's 2nd Annual Orthopedic Conference presentation is as of February
13, 2007 and the Company undertakes no duty to update this information.
Certain statements made throughout this press release that are not
historical facts contain forward-looking statements (as such are defined in
the Private Securities Litigation Reform Act of 1995) regarding the
Company's future plans, objectives and expected performance. Any such
forward-looking statements are based on assumptions that the Company
believes are reasonable, but are subject to a wide range of risks and
uncertainties and, therefore, there can be no assurance that actual results
may not differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause actual results to
differ materially include, but are not limited to, an inability to obtain,
or a delay in obtaining, regulatory approval of new products, differences
in anticipated and actual product and service introduction dates, the
ultimate success of those products in the market place, the continued
acceptance and growth of current products and services, the impact of
competitive products and services, the availability of sufficient
quantities of suitable donated tissue and the success of cost control and
margin improvement efforts. Certain of these factors are detailed from time
to time in the Company's periodic reports filed with the Securities and
Exchange Commission.
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a leading
provider of human bone and bone connective tissue for transplantation and
an innovator in the development and marketing of biomaterial and implant
products for musculoskeletal surgery. For further information regarding
Osteotech or this press release, please go to Osteotech's website at
http://www.osteotech.com.
SOURCE Osteotech, Inc.
 back to top
Related links:
http://www.osteotech.com
http://www.prnewswire.com/comp/668050.html /
CONTACT:
Mark H. Burroughs, Osteotech, +1-732-542-2800
|
